Chromosomal assessment to diagnose urogenital malignancy in dogs

1. A method for diagnosing and treating a urogenital malignancy in a dog, the method comprising:

(a) measuring a copy number of CFA 13, CFA 19, CFA 36, or any combination thereof in a biological sample from a dog; wherein:

(i) the biological sample is selected from the group consisting of a urine sample, cells isolated from the urinary tract of the dog, and a combination thereof; and

(ii) the copy number of CFA 13, 19, and/or 36 is measured by aberrations at CFA chr13:35-36 Mb, CFA chr13:8630922-8818498, CFA chr19:25-26 Mb, and/or CFA chr36:23-24 Mb using canfam2;

(b) detecting an elevated copy number of CFA 13 and/or CFA 36 compared to a normal control or a reduced copy number of CFA 19 compared to a normal control;

(c) diagnosing a urogenital malignancy in the dog; and

(d) treating the urogenital malignancy in the dog with surgery, radiation therapy, chemotherapy, or any combination thereof.

2. The method of claim 1 , wherein the copy number of CFA 13, CFA 19 and CFA 36 are measured.

3. The method of claim 1 , wherein the copy number(s) is measured by fluorescence in situ hybridization (FISH).

4. The method of claim 1 , wherein the copy number(s) is measured by polymerase chain reaction (PCR).

5. The method of claim 1 , wherein the copy number(s) is measured by comparative genomic hybridization (CCH).

6. The method of claim 1 , wherein the copy number(s) is measured by next generation sequencing.

7. The method of claim 1 , wherein the biological sample is a urine sample.

8. The method of claim 1 , wherein the sample is a fresh-frozen sample.

9. The method of claim 1 , wherein the sample is a fresh sample.

10. The method of claim 1 , wherein the sample is a formalin-fixed, paraffin-embedded sample.

11. The method of claim 1 , wherein aberrations at CFA chr13:8630922-8818498, CFA chr19:25119452-25264995, and CFA chr36:23199386-23269766 are measured.

12. A method for selecting and treating a dog for a urogenital malignancy, the method comprising:

(a) measuring a copy number of CFA chr13:35-36 Mb, CFA chr13:8630922-8818498, CFA chr19:25-26 Mb, and/or CFA chr36:23-24 Mb in a biological sample from a dog, wherein the biological sample is selected from the group consisting of a urine sample, cells isolated from the urinary tract of the dog, or a combination thereof isolated from the dog using canfam2;

(b) detecting an elevated copy number of CFA chr13:35-36 Mb, CFA chr13:8630922-8818498, and/or CFA chr36:23-24 Mb compared to a normal control or a reduced copy number of CFA chr19:25-26 Mb compared to a normal control;

(c) diagnosing a urogenital malignancy in the dog; and

(d) selecting and treating the dog for the urogenital malignancy, wherein the treating comprises surgery, radiation therapy, chemotherapy, or any combination thereof.

13. The method of claim 12 , wherein the copy numbers of CFA chr13:35-36 Mb, CFA chr19:25-26 Mb, and CFA chr36:23-24 Mb are measured.

14. The method of claim 12 , wherein the sample is a fresh-frozen sample.

15. The method of claim 12 , wherein the sample is a fresh sample.

16. The method of claim 12 , wherein the sample is a formalin-fixed, paraffin-embedded sample.

17. The method of claim 12 , wherein aberrations at CFA chr13:8630922-8818498, CFA chr19:25119452-25264995, and CFA chr36:23199386-23269766 are measured.